Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ashley Frith (NPI 1730352014)

Field	Value
Entity Type	Individual
Organization	Ashley Frith
Address	150 Entrance Way
City	Saint Peters
State	MO
ZIP	63376
Taxonomy	Medical Oncology Physician
NPI Enumerated	April 8, 2008

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider is operating as a medically focused oncology/infusion practice: the highest-revenue Medicare codes are injectable oncologic and biologic therapies (J9271, J9144, J1561), together with chemotherapy administration and infusion-related procedure codes. The code mix emphasizes outpatient intravenous biologic and cytotoxic drug delivery rather than primary care evaluation and management.

Revenue is heavily concentrated in a small set of infused biologics: the top three Medicare codes (J9271, J9144, J1561) account for 58.9% of the provider's total Medicare revenue. Individually those codes represent $455.8K (33.4%) for J9271, $205.2K (15.0%) for J9144, and $143.6K (10.5%) for J1561, showing that a few high-cost drugs drive most billed dollars.

The provider is effectively single-payer in the available data: lifetime Medicare revenue is $1.4M while there is no Medicaid billing on file. This concentration means Medicare activity wholly dominates the observable revenue picture and should be treated as the primary payer relationship for network or contracting analysis.

On competitive standing for the top drug codes the provider is a modest national participant rather than a dominant center: J9271 ranks #1102 of 1841 providers nationally (39th percentile; typical, unremarkable volume for this code), J9144 ranks #467 of 615 (23th percentile; typical, unremarkable volume for this code), and J1561 ranks #89 of 180 (51th percentile; typical, unremarkable volume for this code). These ranks indicate routine use of these agents but not a top-volume specialty hub at the national level.

Certain infusion and procedure codes are statistical outliers in the upward direction, signaling strong procedural throughput: 96413 (chemotherapy administration) appears as notably above typical national volume with 587 claims generating $58.1K (4.3% of Medicare revenue) and a 94th percentile rank, while 36430 (venous catheter placement) ranks 3 of 94 providers nationally (98th percentile; notably above typical) with 129 claims and $3.9K (0.3%). These elevated procedure volumes are consistent with a practice that performs frequent infusions and vascular access procedures.

The provider also bills for supportive hematology services and transfusions, indicating an on-site capability for blood product and growth-factor support: J2506 (pegfilgrastim) accounts for $54.4K (4.0%), P9073 (pathogen-reduced platelets) $30.8K (2.3%), and P9040 (irradiated red blood cells) $23.7K (1.7%). Ranks for these codes vary (for example P9073 ranks #3 of 4 nationally, 33th percentile), but the presence and dollar amounts show a bundled oncology infusion and transfusion service line.

Evaluation-and-management revenue is small relative to drug and procedure revenue, reinforcing an infusion-centric business model: 99213 produced $21.6K (1.6%) and 99214 produced $20.7K (1.5%) of Medicare revenue. This pattern suggests the practice’s financial footprint is driven by high-cost injectable therapies and procedures rather than office visit volume.

The provider has long-standing Medicare enrollment (NPI enumerated 2008-04-08 (~18 years ago)), indicating an established operating history. Combined with the concentrated drug revenue and elevated procedure ranks, the tenure supports the interpretation of a mature oncology infusion operation with sustained Medicare activity rather than a newly formed practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

54 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,600	$40	$455.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,400	$40	$205.2K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	3,780	$40	$143.6K
J0897	Injection, denosumab, 1 mg	7,260	$20	$130.7K
J9047	Injection, carfilzomib, 1 mg	3,770	$30	$113.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$100	$58.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	670	$80	$54.4K
P9073	Platelets, pheresis, pathogen-reduced, each unit	40	$720	$30.8K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	100	$230	$23.7K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	170	$130	$23K

Showing 1–10 of 54

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 54 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Ashley Frith — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

54 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	20	40	9,100	$40	$502K
J9144	16	20	7,200	$40	$308.4K
J9047	1	10	3,770	$30	$111.3K
J1561	5	30	1,650	$40	$87.1K
J0897	30	210	2,400	$20	$82.4K
P9073	1	10	40	$710	$27.1K
J2506	1	40	310	$80	$25.9K
96413	12	160	140	$100	$19.1K
J9217	17	70	100	$130	$17.7K
J3490	14	80	40	$150	$14K

Showing 1–10 of 54

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ashley Frith, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Washington University	MO	Multi-Specialty Clinic/Center	$0	$22M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$14.8M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$10.4M
Washington University	MO	Emergency Care Clinic/Center	$0	$9.1M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$6.9M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.4M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$4M
John Visconti	IL	Medical Oncology Physician	$2.8M	$149.1K
Peter Oppelt	MO	Medical Oncology Physician	$2.5M	$15.8K
Ronald Dean	MT	Emergency Medicine Physician	$2.3M	$2.3K

Nearby Providers

Other providers in the same ZIP code as Ashley Frith, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Handicap Facilities Of St Charles County	MO	Case Management Agency	$0	$29.7M
Commun Ity Living For The Handicapped Inc.	MO	Developmentally Disabled Services Day Training Agency	$0	$25.6M
Community Living For The Handicapped Inc.	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$23.7M
Delta Center Personal Attendant Services	MO	In Home Supportive Care Agency	$0	$22.5M
St. Charles County Ambulance District	MO	Land Ambulance	$3.4M	$10.7M
Shanee Woodard	MO	In Home Supportive Care Agency	$0	$8.8M
Resolutions For People, LLC	MO	In Home Supportive Care Agency	$0	$7.9M
Mcclay Adult Day Center LLC	MO	Adult Day Care Clinic/Center	$0	$4.8M
Barnes Jewish St Peters Hospital Inc	MO	General Acute Care Hospital	$0	$4.4M
Caron Rigden	MO	Medical Oncology Physician	$1.6M	$0

Ashley Frith — Billing Profile & Reimbursement Data

Sign up for Ashley Frith — Billing Profile & Reimbursement Data policy alerts

Ashley Frith — Billing Profile & Reimbursement Data

Sign up for Ashley Frith — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References